Lipocalin-2 as a prognostic biomarker and its association with systemic inflammation in small cell lung cancer.

ABSTRACT:

Background

Systemic inflammation is believed to contribute to small cell lung cancer (SCLC) progression, but the underlying relationship remains unclear. Lipocalin-2, a potential biomarker of inflammation, has been implicated in various cancers but its prognostic value in SCLC is underexplored.

Methods

We retrospectively analyzed 191 patients with SCLC (72 with limited-stage [LD] and 119 with extensive-stage) treated using platinum-based chemotherapy. Lipocalin-2 expression was evaluated using immunohistochemistry. Optimal cutoff values for lipocalin-2 and neutrophil-to-lymphocyte ratio (NLR) were determined using time-dependent receiver operating characteristic curve analysis. The pectoralis muscle index was used to assess sarcopenia.

Results

In LD-SCLC, high lipocal

SUBMITTER: Go SI 

PROVIDER: S-EPMC11260553 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature